There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
ACADEMIA
Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
Particles of stainless steel found in some vials of Moderna’s COVID-19 vaccine are unlikely to cause systemic symptoms even if it is administered to people, the Japanese Society for Vaccinology said in a statement issued on September 7. The statement…
To read the full story
Related Article
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- “Human Error” Is to Blame for Contamination of Moderna COVID-19 Vaccines: Report
October 4, 2021
- Tainted Moderna Jabs Run Afoul of PMD Law: Minister
September 16, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- Post-Vaccination Death Cases Being Investigated with Integrity: Takeda
September 8, 2021
- Man Died after Getting Moderna Jab Subject to Recall, 3rd Such Case in Japan
September 7, 2021
- Takeda Recalling Suspended Batches of Moderna Jabs in Japan; Administrative Action Possible
September 2, 2021
- 2 Died after Getting Moderna Shots from Suspended Batch: MHLW
August 30, 2021
ACADEMIA
- Japan Pediatric Society Recommends COVID Jab for Ages 5-17
August 12, 2022
- High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor
August 5, 2022
- 7 Japan Scientific Societies Issue Proposal on Development of Vaccines, Anti-Infectives
August 3, 2022
- Deregulation Likely to Create 1.15 Trillion Yen Headroom for Switched OTC Growth: Health Economist
July 15, 2022
- Gynecologist Cautious about Inclusion of Pregnant Women in Clinical Trials, but Says ICH Move Will Spark Safety Discussions
July 14, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…